EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Marburg self-amplifying mRNA-lipid nanoparticle vaccine: differential effects when co-formulated with Toll-like Receptor agonists

Mhd Anas Tomeh, Gillian Hoover, Sarah Horst, Erik de Leeuw, Murty Chengalvala, Robin Shattock, Allan Watkinson

RSC Pharmaceutics · 2026 · 3 (4) · 1086-1101

DOI: 10.1039/d6pm00134c ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Mhd Anas Tomeh und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schematic representation of Marburg saRNA-LNP vaccine formulations and the type of targeted receptors.

Zitieren

APA

Tomeh, M. A., Hoover, G., Horst, S., Leeuw, E. D., Chengalvala, M., Shattock, R., & Watkinson, A. (2026). Marburg self-amplifying mRNA-lipid nanoparticle vaccine: differential effects when co-formulated with Toll-like Receptor agonists. RSC Pharmaceutics, 3(4), 1086-1101. https://doi.org/10.1039/d6pm00134c

Vancouver

Tomeh MA, Hoover G, Horst S, Leeuw ED, Chengalvala M, Shattock R, et al. Marburg self-amplifying mRNA-lipid nanoparticle vaccine: differential effects when co-formulated with Toll-like Receptor agonists. RSC Pharmaceutics. 2026;3(4):1086-1101. doi:10.1039/d6pm00134c

BibTeX
@article{Tomeh2026,
  author = {Tomeh, Mhd Anas and Hoover, Gillian and Horst, Sarah and Leeuw, Erik de and Chengalvala, Murty and Shattock, Robin and Watkinson, Allan},
  title = {Marburg self-amplifying mRNA-lipid nanoparticle vaccine: differential effects when co-formulated with Toll-like Receptor agonists},
  journal = {RSC Pharmaceutics},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {1086--1101},
  doi = {10.1039/d6pm00134c}
}
Kostenlos starten →